Orikami and Amgen Netherlands personalize care for lung cancer patients Nijmegen, May 8th 2023 Dutch Medtech organization Orikami and biopharmaceutical company Amgen Netherlands have taken up the challenge to personalize care for lung cancer…
Our mission - to improve 100 million lives before 2030 by enabling personalized healthcare.
We believe health data is underutilized. We use real-world patient data to enable personalized healthcare paths for our clients to improve their quality of life. Therefore, we develop digital biomarkers.
VALUE of Digital Biomarkers
What are digital biomarkers?
Digital biomarkers are defined as objective, quantifiable physiological and behavioral data. They are collected and measured by means of digital devices such as portables, wearables, implantables or digestibles.
Clinical validated digital biomarkers provide objective data that provides clinically significant results. This enables decision support to clinicians and will optimize patients’ health paths.
Quality Management Certificate EN-ISO 13485: 2016
Orikami develops digital solutions for remote home monitoring according to the highest quality standards of the European Medical Device Regulation (MDR). Earlier this year we started the certification process of our Quality Management System according to…